Tectonic Therapeutic, Inc. Cash Flow Conversion Efficiency
Tectonic Therapeutic, Inc. cash flow conversion efficiency. Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) has a cash flow conversion efficiency ratio of -0.096x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.45 Million) by net assets ($223.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tectonic Therapeutic, Inc. (2016–2025)
Cash flow conversion efficiency of Tectonic Therapeutic, Inc. from 2016 to 2025. This chart illustrates how Tectonic Therapeutic, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Tectonic Therapeutic, Inc. for real-time trading data and today's change.
Tectonic Therapeutic, Inc. Cash Flow Conversion Ratio Explained
Tectonic Therapeutic, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tectonic Therapeutic, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tectonic Therapeutic, Inc. ranked by their cash flow conversion efficiency. Also see Tectonic Therapeutic, Inc. (TECX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
USI Corp
TW:1304
|
-0.006x |
|
Huchems
KO:069260
|
0.030x |
|
Jiangsu Huifeng Agrochemical Co Ltd
SHE:002496
|
0.002x |
|
Luoyang Glass
SHG:600876
|
0.003x |
|
Bafang Yunji Intl Co Ltd
TW:2753
|
0.107x |
|
Shanghai Nar Industrial Co Ltd
SHE:002825
|
0.018x |
|
LF Corp
KO:093050
|
0.034x |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
0.399x |
Annual Cash Flow Conversion Efficiency for Tectonic Therapeutic, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Tectonic Therapeutic, Inc. from 2016 to 2025. Review Tectonic Therapeutic, Inc. (TECX) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $251.33 Million | $-60.08 Million | -0.239x | +43.04% |
| 2024-12-31 | $140.78 Million | $-59.08 Million | -0.420x | -187.31% |
| 2023-12-31 | $-84.64 Million | $-40.68 Million | 0.481x | -77.43% |
| 2022-12-31 | $-45.65 Million | $-97.21 Million | 2.129x | +155.77% |
| 2021-12-31 | $-14.96 Million | $-12.45 Million | 0.832x | +314.30% |
| 2020-12-31 | $254.34 Million | $-98.80 Million | -0.388x | -6.78% |
| 2019-12-31 | $186.01 Million | $-67.67 Million | -0.364x | -18.06% |
| 2018-12-31 | $122.18 Million | $-37.65 Million | -0.308x | +93.67% |
| 2017-12-31 | $3.37 Million | $-16.38 Million | -4.868x | -549.46% |
| 2016-12-31 | $4.42 Million | $-3.31 Million | -0.750x | -- |
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more